A recent study suggests that individuals taking GLP-1 medications may have an 18% lower risk of developing age-related macular degeneration (AMD), a condition affecting central vision. This finding, based on health records of nearly 158,000 adults aged 60 and older, indicates a…
Research presented at the EADV Congress 2026 highlights significant rates of nail detachment and hair loss among users of GLP-1 medications for obesity and diabetes, compared to n…
The protein market has seen significant growth, estimated to exceed $50 billion globally, with Irish companies like Glanbia leading the way. While protein is essential for health,…
Eli Lilly's experimental obesity treatment, combining eloralintide and Mounjaro, has demonstrated an average weight loss of 23% in individuals with diabetes, highlighting its pote…
A new statement from the American College of Cardiology emphasizes the significance of overall dietary patterns over individual nutrients in promoting heart health. It advocates f…
Recent developments in weight-loss medications highlight the potential of amylin-based drugs, which may offer effective weight management with fewer gastrointestinal side effects…
As the popularity of GLP-1 weight-loss medications like Ozempic and Wegovy rises, concerns emerge regarding their impact on brain health. Dr. Tommy Wood emphasizes that rapid weig…
Recent research suggests that Ozempic-like medications, which include semaglutide, may influence alcohol cravings and consumption patterns. While some studies indicate a reduction…
Recent clinical trial data reveals that Retatrutide, a new obesity treatment, resulted in an average weight loss of 25% after 80 weeks and 30% after 104 weeks among participants.…
A recent study published in the journal Obesity investigates the effects of time-restricted eating on weight loss and eating behaviors in adults with obesity and prediabetes. The…
A recent study published in JAMA Health Forum reveals that high out-of-pocket costs significantly affect patient adherence to GLP-1 weight loss medications. The research indicates…
A recent study published in the journal Childhood Obesity reveals that approximately 16.8% of children aged 10 to 17 who began treatment with GLP-1 receptor agonist medications de…
Sofia Carson has come under fire for her appearance at the LACMA Art+Film Gala, with fans expressing concern over Hollywood's extreme beauty standards. The backlash highlights a g…
Beauty companies are racing to address the newly coined term 'Ozempic face' as they develop treatments for facial volume loss linked to rapid weight loss, further complicating the…
Fitness coach Jacob Zemer outlines key strategies to help adults slow muscle loss as they age. He emphasizes the importance of strength training, adequate protein intake, and qual…
NVIDIA and Eli Lilly have both reported impressive quarterly earnings, showcasing their respective growth potential. NVIDIA's revenue surged by over 105% year-over-year, driven by…
Novo Nordisk's stock fell by 7% after the company revealed its long-term growth strategy at a capital markets day, raising investor concerns about its ability to maintain its posi…
In a stunning twist of regulatory fate, the FDA has issued new hair-raising guidelines for users of GLP-1 drugs like Ozempic and Mounjaro, warning of a 37-68% increased risk of ha…